CanadaTuberculosis profile
Population  2015 36 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.11 (0.1–0.11) 0.29 (0.29–0.3)
Mortality (HIV+TB only) 0.019 (<0.01–0.096) 0.05 (0–0.27)
Incidence  (includes HIV+TB) 1.8 (1.6–2.1) 5.1 (4.3–5.8)
Incidence (HIV+TB only) 0.15 (0.12–0.17) 0.4 (0.33–0.48)
Incidence (MDR/RR-TB)** 0.031 (0.016–0.045) 0.09 (0.04–0.13)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.058 (0.032–0.084) 0.74 (0.56–0.92) 0.8 (0.59–1)
Males 0.055 (0.036–0.074) 0.97 (0.76–1.2) 1 (0.8–1.3)
Total 0.11 (0.08–0.15) 1.7 (1.6–1.9) 1.8 (1.6–2.1)
TB case notifications, 2015  
Total cases notified 1 640
Total new and relapse 1 640
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 44%
          - % pulmonary 70%
          - % bacteriologically confirmed among pulmonary 80%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 90% (78–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.07 (0.04–0.1)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 58 8%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  16
(8–25)
Estimated % of TB cases with MDR/RR-TB 1.4% (0.72–2.4) 1.8% (0.05–9.6)  
% notified tested for rifampicin resistance 76% 78% 1 268
MDR/RR-TB cases tested for resistance to second-line drugs   19
Laboratory-confirmed cases MDR/RR-TB: 19, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: , XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 82% 1 612
Previously treated cases, excluding relapse, registered in 2014    
HIV-positive TB cases, all types, registered in 2014 74% 65
MDR/RR-TB cases started on second-line treatment in 2013 67% 15
XDR-TB cases started on second-line treatment in 2013 100% 1
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data